Advanced & Next-Gen Proteomics - Director of Biomarkers, National Commercial Reference Lab

The Director of Biomarkers at a national commercial reference lab discusses the use of next-generation proteomics technologies and the challenges of adopting them in a large CRO setting. They discuss the use of MSD, ELISA, and fluorescence-based assays in applications such as therapeutic response monitoring and therapeutic target validation. Use cases and adoption of new technologies are reactive to biopharma needs, and selecting assays and workflows is a balancing act of cost, throughput, and assay specifications to meet client needs. Reproducibility is seen as a key pain point, a challenge that must be addressed for these tools to see more widespread adoption in clinical trials. This CRO has been in months long talks with Olink, but they have not yet adopted this tech because no clients have required this specific technology in experiments to date.

‍